Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab in Idiopathic Pulmonary Fibrosis
NCT05130970Phase 2Completed
- Sponsor
- CSL Limited
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of garadacimab in idiopathic pulmonary fibrosis (IPF), sponsored by CSL Limited. Started Feb 2022; status: completed.
02
Drugs
garadacimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05130970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130970.